Evan Seigerman

Can you just talk to me about the level of appetite for additional BD and liver-focused indications such as NASH

If PrEP is removed as a preventative medicine broadly, how does this change your approach to commercialization

Are you seeing more share or competitive share capture from competitive cell therapy products or bispecifics

A year from now on this call, I'd love for you to characterize what you would ask for a good product launch

could you expand on what drives this view and how it has changed since the initiation of the program

can you provide some practical examples of what you and the industry can do to help achieve the goals of getting price parity globally?

Can you provide some additional detail on what FDA wants to see in regard to additional data and what you didn't have from the SUMMIT trial

contextualize the importance of a dual regimen versus the standard of care of bictegravir Biktarvy

can you just talk about the initial feedback, say, versus the competition

I'd love if you could expand on your approach to diligencing assets between Chinese and Western companies

How what are some metrics you're putting around that? And more broadly, I just want to ensure that this is going to derive a good return

Assuming Metsera closes, what near-term factors must you consider to continue growing the dividend and then delevering

what do you believe are the 2 or 3 assets that have the potential to really drive a positive IRR for the $42 billion or so that you spent?

What are some key aspects of the profile that you're looking for either from an internal perspective or potentially externally?

can you walk me through how you plan on working with him as a likely head of HHS, especially with his views on vaccines